The study showed that the low expression of ICAM-1 in BC cells creates resistance to trastuzumab-triggered ADCC, whereas genetically engineered CAR-NKs remain effective regardless of ICAM-1 expression levels. The gene discussed is ICAM1; the disease is breast cancer.